Dossier
personalized cancer vaccine
Coverage of personalized cancer vaccine in the Nexus archive.
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
A personalized cancer vaccine from Moderna and Merck showed promise during a late-stage melanoma trial. The study found that the combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.